- Home
- IPA vs CODX Comparison
IPA vs CODX Comparison
Compare IPA & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- CODX
- Stock Information
- Founded
- IPA 1983
- CODX 2013
- Country
- IPA Canada
- CODX United States
- Employees
- IPA N/A
- CODX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- IPA Health Care
- CODX Health Care
- Exchange
- IPA Nasdaq
- CODX Nasdaq
- Market Cap
- IPA 19.9M
- CODX 39.3M
- IPO Year
- IPA 2017
- CODX 2017
- Fundamental
- Price
- IPA $0.54
- CODX $1.25
- Analyst Decision
- IPA Strong Buy
- CODX Hold
- Analyst Count
- IPA 2
- CODX 1
- Target Price
- IPA $6.00
- CODX $1.50
- AVG Volume (30 Days)
- IPA 316.7K
- CODX 93.8K
- Earning Date
- IPA 12-12-2024
- CODX 11-07-2024
- Dividend Yield
- IPA N/A
- CODX N/A
- EPS Growth
- IPA N/A
- CODX N/A
- EPS
- IPA N/A
- CODX N/A
- Revenue
- IPA $17,441,886.00
- CODX $9,136,969.00
- Revenue This Year
- IPA $4.33
- CODX N/A
- Revenue Next Year
- IPA $35.64
- CODX N/A
- P/E Ratio
- IPA N/A
- CODX N/A
- Revenue Growth
- IPA 11.21
- CODX 25.24
- 52 Week Low
- IPA $0.46
- CODX $1.00
- 52 Week High
- IPA $2.60
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- IPA 36.16
- CODX 48.21
- Support Level
- IPA $0.56
- CODX $1.22
- Resistance Level
- IPA $0.65
- CODX $1.35
- Average True Range (ATR)
- IPA 0.06
- CODX 0.09
- MACD
- IPA -0.00
- CODX 0.00
- Stochastic Oscillator
- IPA 34.15
- CODX 40.00
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.